MOTS-c vs Semaglutide
Both MOTS-c and Semaglutide are used for metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Semaglutide
Evidence A+Semaglutide (Ozempic / Wegovy)
A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.
View full Semaglutide profile →Side-by-Side
| Attribute | MOTS-c | Semaglutide |
|---|---|---|
| Evidence Grade | B | A+ |
| FDA Status | Not FDA-approved — research peptide; multiple early-phase clinical trials | FDA-approved for weight management and type 2 diabetes |
| Typical Dose | 5–10 mg, 2–3 times weekly (subcutaneous) | 0.25–2.4 mg weekly (subcutaneous injection) |
| Clinics Indexed | 22 | 2,285 |
| Categories | metabolic, longevity | weight-loss, metabolic |
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Key reported benefits — Semaglutide
- ✓Significant weight loss
- ✓Appetite suppression
- ✓Blood sugar control
- ✓Cardiovascular benefit
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.